1
|
Soriano-Ursúa MA, Arias-Montaño JA, Ocampo-Néstor AL, Hernández-Martínez CF, Santillán-Torres I, Andrade-Jorge E, Valdez-Ortiz R, Fernández-Del Valle C, Trujillo-Ferrara JG. In silico identification of a biarylamine acting as agonist at human β 3 adrenoceptors and exerting BRL37344-like effects on mouse metabolism. NAUNYN-SCHMIEDEBERG'S ARCHIVES OF PHARMACOLOGY 2024; 397:2159-2170. [PMID: 37792048 DOI: 10.1007/s00210-023-02753-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/20/2023] [Accepted: 09/26/2023] [Indexed: 10/05/2023]
Abstract
Human β3-adrenoceptor (β3AR) agonists were considered potential agents for the treatment of metabolic disorders. However, compounds tested as β3AR ligands have shown marked differences in pharmacological profile in rodent and human species, although these compounds remain attractive as they were successfully repurposed for the therapy of urinary incontinence. In this work, some biarylamine compounds were designed and tested in silico as potential β3AR agonists on 3-D models of mouse or human β3ARs. Based on the theoretical results, we identified, synthesized and tested a biarylamine compound (polibegron). In CHO-K1 cells expressing the human β3AR, polibegron and the β3AR agonist BRL 37344 were partial agonists for stimulating cAMP accumulation (50 and 57% of the response to isoproterenol, respectively). The potency of polibegron was 1.71- and 4.5-fold higher than that of isoproterenol and BRL37344, respectively. These results indicate that polibegron acts as a potent, but partial, agonist at human β3ARs. In C57BL/6N mice with obesity induced by a high-fat diet, similar effects of the equimolar intraperitoneal administration of polibegron and BRL37344 were observed on weight, visceral fat and plasma levels of glucose, cholesterol and triglycerides. Similarities and differences between species related to ligand-receptor interactions can be useful for drug designing.
Collapse
Affiliation(s)
- Marvin A Soriano-Ursúa
- Departamentos de Fisiología, Bioquímica y Sección de Estudios de Posgrado E Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Plan de San Luis y Díaz Mirón, 11340, Mexico City, Mexico.
| | - José-Antonio Arias-Montaño
- Departamento de Fisiología, Biofísica y Neurociencias, Centro de Investigación y de Estudios Avanzados del I.P.N., Av. IPN 2508, 07360, Mexico City, Mexico
| | - Ana-Lilia Ocampo-Néstor
- Departamentos de Fisiología, Bioquímica y Sección de Estudios de Posgrado E Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Plan de San Luis y Díaz Mirón, 11340, Mexico City, Mexico
- Departamento de Nefrología, Hospital General de México "Dr. Eduardo Liceaga", Dr. Balmis 148, Alc. Cuauhtémoc, 06720, Mexico City, Mexico
| | - Christian F Hernández-Martínez
- Departamentos de Fisiología, Bioquímica y Sección de Estudios de Posgrado E Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Plan de San Luis y Díaz Mirón, 11340, Mexico City, Mexico
| | - Iván Santillán-Torres
- Departamento de Fisiología, Biofísica y Neurociencias, Centro de Investigación y de Estudios Avanzados del I.P.N., Av. IPN 2508, 07360, Mexico City, Mexico
| | - Erik Andrade-Jorge
- Departamentos de Fisiología, Bioquímica y Sección de Estudios de Posgrado E Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Plan de San Luis y Díaz Mirón, 11340, Mexico City, Mexico
| | - Rafael Valdez-Ortiz
- Departamento de Nefrología, Hospital General de México "Dr. Eduardo Liceaga", Dr. Balmis 148, Alc. Cuauhtémoc, 06720, Mexico City, Mexico
| | - Cecilia Fernández-Del Valle
- Área de Investigación Médica, Productos Medix, S.A. de C.V., Calzada del Hueso 39, Ejido Viejo Santa Úrsula Coapa, Coyoacán, 04650, Mexico City, Mexico
| | - José G Trujillo-Ferrara
- Departamentos de Fisiología, Bioquímica y Sección de Estudios de Posgrado E Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Plan de San Luis y Díaz Mirón, 11340, Mexico City, Mexico.
| |
Collapse
|
2
|
New drug approvals for 2020: Synthesis and clinical applications. Eur J Med Chem 2021; 215:113284. [PMID: 33611190 DOI: 10.1016/j.ejmech.2021.113284] [Citation(s) in RCA: 27] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2021] [Revised: 02/03/2021] [Accepted: 02/03/2021] [Indexed: 02/06/2023]
Abstract
53 New drugs including 38 chemical entities and 15 biologics were approved by the U.S. Food and Drug Administration during 2020. Among the marketed drugs, 34 new small molecule drugs and 4 new diagnostic agents with privileged structures and novel clinical applications represent as promising leads for the development of new drugs with the similar indications and improved therapeutic efficacy. This review is mainly focused on the clinical applications and synthetic methods of 34 small-molecule drugs newly approved by the FDA in 2020.
Collapse
|
3
|
Ocampo-Néstor AL, López-Mayorga RM, Castillo-Henkel EF, Padilla-Martínez II, Trujillo-Ferrara JG, Soriano-Ursúa MA. Design, synthesis and in vitro evaluation of a Dopa-organoboron compound that acts as a bladder relaxant through non-catecholamine receptors. Mol Divers 2019; 23:361-370. [PMID: 30284107 DOI: 10.1007/s11030-018-9883-7] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2018] [Accepted: 09/25/2018] [Indexed: 02/07/2023]
Abstract
Bladder relaxation through drug administration is an interesting topic in medicinal and combinatorial chemistry. In fact, compounds targeting catecholamine receptors [dopamine receptors and beta-adrenergic receptors (βAR) expressed in the bladder] are among the compounds commonly employed for this purpose. In particular, recent investigations have tended to focus on the β3-adrenoceptor (β3AR) as a target in the treatment of urinary incontinence and other disorders. However, organoboron compounds have been suggested as potent and efficient agents on these drug targets. In this work, through a docking study, we identified the parameters that induce a theoretical improvement in the affinity and activity of the organoboron compounds on the catecholamine receptors expressed in the bladder. Then, the identified potential drug, a boron-containing dopa-derivative named DPBX-L-Dopa, was synthesized and characterized. This compound induces a relaxation on the smooth muscle of the rat bladder, behaving as a weak relaxant compared to isoproterenol but with similar efficacy to BRL377, a selective β3AR agonist. However, unexpectedly, this effect was not blocked by propranolol or haloperidol at the concentrations at which they are able to block the catecholamine receptors in bladder tissue. In view of these results, the effect of DPBX-L-Dopa compound on the alpha 1 adrenergic receptors (α1AR) of aorta of the rats was also explored; however, no response of the tissue to this compound was obtained. The possible mechanisms of the action of this compound were explored and are discussed further.
Collapse
Affiliation(s)
- Ana L Ocampo-Néstor
- Departamento de Fisiología, Laboratorio de Investigación en Bioquímica y Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Plan de San Luis y Díaz Mirón, 11340, México, Mexico
| | - Ruth M López-Mayorga
- Departamento de Fisiología, Laboratorio de Investigación en Bioquímica y Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Plan de San Luis y Díaz Mirón, 11340, México, Mexico
| | - Enrique F Castillo-Henkel
- Departamento de Fisiología, Laboratorio de Investigación en Bioquímica y Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Plan de San Luis y Díaz Mirón, 11340, México, Mexico
| | - Itzia I Padilla-Martínez
- Unidad Profesional Interdisciplinaria de Biotecnología, Instituto Politécnico Nacional, Avenida Acueducto s/n, Barrio La Laguna Ticomán, 07340, México, Mexico
| | - José G Trujillo-Ferrara
- Departamento de Fisiología, Laboratorio de Investigación en Bioquímica y Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Plan de San Luis y Díaz Mirón, 11340, México, Mexico.
| | - Marvin A Soriano-Ursúa
- Departamento de Fisiología, Laboratorio de Investigación en Bioquímica y Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Plan de San Luis y Díaz Mirón, 11340, México, Mexico.
| |
Collapse
|
4
|
Ocampo-Néstor AL, López-Mayorga RM, Castillo-Henkel EF, Padilla-Martínez II, Trujillo-Ferrara JG, Soriano-Ursúa MA. Design, synthesis and in vitro evaluation of a Dopa-organoboron compound that acts as a bladder relaxant through non-catecholamine receptors. Mol Divers 2018. [PMID: 30284107 DOI: 10.1007/s11030-018-9883-7.] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/29/2022]
Abstract
Bladder relaxation through drug administration is an interesting topic in medicinal and combinatorial chemistry. In fact, compounds targeting catecholamine receptors [dopamine receptors and beta-adrenergic receptors (βAR) expressed in the bladder] are among the compounds commonly employed for this purpose. In particular, recent investigations have tended to focus on the β3-adrenoceptor (β3AR) as a target in the treatment of urinary incontinence and other disorders. However, organoboron compounds have been suggested as potent and efficient agents on these drug targets. In this work, through a docking study, we identified the parameters that induce a theoretical improvement in the affinity and activity of the organoboron compounds on the catecholamine receptors expressed in the bladder. Then, the identified potential drug, a boron-containing dopa-derivative named DPBX-L-Dopa, was synthesized and characterized. This compound induces a relaxation on the smooth muscle of the rat bladder, behaving as a weak relaxant compared to isoproterenol but with similar efficacy to BRL377, a selective β3AR agonist. However, unexpectedly, this effect was not blocked by propranolol or haloperidol at the concentrations at which they are able to block the catecholamine receptors in bladder tissue. In view of these results, the effect of DPBX-L-Dopa compound on the alpha 1 adrenergic receptors (α1AR) of aorta of the rats was also explored; however, no response of the tissue to this compound was obtained. The possible mechanisms of the action of this compound were explored and are discussed further.
Collapse
Affiliation(s)
- Ana L Ocampo-Néstor
- Departamento de Fisiología, Laboratorio de Investigación en Bioquímica y Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Plan de San Luis y Díaz Mirón, 11340, México, Mexico
| | - Ruth M López-Mayorga
- Departamento de Fisiología, Laboratorio de Investigación en Bioquímica y Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Plan de San Luis y Díaz Mirón, 11340, México, Mexico
| | - Enrique F Castillo-Henkel
- Departamento de Fisiología, Laboratorio de Investigación en Bioquímica y Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Plan de San Luis y Díaz Mirón, 11340, México, Mexico
| | - Itzia I Padilla-Martínez
- Unidad Profesional Interdisciplinaria de Biotecnología, Instituto Politécnico Nacional, Avenida Acueducto s/n, Barrio La Laguna Ticomán, 07340, México, Mexico
| | - José G Trujillo-Ferrara
- Departamento de Fisiología, Laboratorio de Investigación en Bioquímica y Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Plan de San Luis y Díaz Mirón, 11340, México, Mexico.
| | - Marvin A Soriano-Ursúa
- Departamento de Fisiología, Laboratorio de Investigación en Bioquímica y Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Plan de San Luis y Díaz Mirón, 11340, México, Mexico.
| |
Collapse
|
5
|
Lorca M, Morales-Verdejo C, Vásquez-Velásquez D, Andrades-Lagos J, Campanini-Salinas J, Soto-Delgado J, Recabarren-Gajardo G, Mella J. Structure-Activity Relationships Based on 3D-QSAR CoMFA/CoMSIA and Design of Aryloxypropanol-Amine Agonists with Selectivity for the Human β3-Adrenergic Receptor and Anti-Obesity and Anti-Diabetic Profiles. Molecules 2018; 23:molecules23051191. [PMID: 29772697 PMCID: PMC6099677 DOI: 10.3390/molecules23051191] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2018] [Revised: 05/10/2018] [Accepted: 05/13/2018] [Indexed: 12/20/2022] Open
Abstract
The wide tissue distribution of the adrenergic β3 receptor makes it a potential target for the treatment of multiple pathologies such as diabetes, obesity, depression, overactive bladder (OAB), and cancer. Currently, there is only one drug on the market, mirabegron, approved for the treatment of OAB. In the present study, we have carried out an extensive structure-activity relationship analysis of a series of 41 aryloxypropanolamine compounds based on three-dimensional quantitative structure-activity relationship (3D-QSAR) techniques. This is the first combined comparative molecular field analysis (CoMFA) and comparative molecular similarity index analysis (CoMSIA) study in a series of selective aryloxypropanolamines displaying anti-diabetes and anti-obesity pharmacological profiles. The best CoMFA and CoMSIA models presented values of r2ncv = 0.993 and 0.984 and values of r2test = 0.865 and 0.918, respectively. The results obtained were subjected to extensive external validation (q2, r2, r2m, etc.) and a final series of compounds was designed and their biological activity was predicted (best pEC50 = 8.561).
Collapse
Affiliation(s)
- Marcos Lorca
- Escuela de Quimica y Farmacia, Facultad de Medicina, Universidad Andres Bello, Quillota 980, Viña del Mar 2531015, Chile.
| | - Cesar Morales-Verdejo
- Centro de Nanotecnología Aplicada, Facultad de Ciencias, Universidad Mayor, Camino la Pirámide 5750, Huechuraba, Santiago 8580000, Chile.
| | - David Vásquez-Velásquez
- Facultad de Ciencias Químicas y Farmacéuticas, Universidad de Chile, Sergio Livingstone 1007, Independencia, Santiago 8380492, Chile.
| | - Juan Andrades-Lagos
- Facultad de Ciencias Químicas y Farmacéuticas, Universidad de Chile, Sergio Livingstone 1007, Independencia, Santiago 8380492, Chile.
| | - Javier Campanini-Salinas
- Facultad de Ciencia, Universidad San Sebastián, Lago Panguipulli 1390, Puerto Montt 5501842, Chile.
| | - Jorge Soto-Delgado
- Departamento de Ciencias Quimicas, Facultad de Ciencias Exactas, Universidad Andres Bello, Quillota 980, Viña del Mar 2531015, Chile.
| | - Gonzalo Recabarren-Gajardo
- Departamento de Farmacia, Facultad de Química, Pontificia Universidad Católica de Chile, Casilla 306, Avda. Vicuña Mackenna 4860, Macul, Santiago 7820436, Chile.
| | - Jaime Mella
- Centro de Investigación Farmacopea Chilena (CIFAR), Universidad de Valparaíso, Av. Gran Bretaña 1111, Valparaíso 2360102, Chile.
- Instituto de Química y Bioquímica, Facultad de Ciencias, Universidad de Valparaíso, Av. Gran Bretaña 1111, Valparaíso 2360102, Chile.
| |
Collapse
|
6
|
Ku AF, Cuny GD. Discovery of 7-hydroxyaporphines as conformationally restricted ligands for beta-1 and beta-2 adrenergic receptors. MEDCHEMCOMM 2018; 9:353-356. [PMID: 30108929 PMCID: PMC6083790 DOI: 10.1039/c7md00656j] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/31/2017] [Accepted: 01/05/2018] [Indexed: 11/21/2022]
Abstract
A series of (-)-nornuciferidine derivatives was synthesized and the non-natural enantiomer of the aporphine alkaloid was discovered to be a potent β1- and β2-adrenergic receptor ligand that antagonized isoproterenol and procaterol induced cyclic AMP increases from adenylyl cyclase, respectively. Progressive deconstruction of the tetracyclic scaffold to less complex cyclic and acyclic analogues revealed that the conformationally restricted (6a-R,7-R)-7-hydroxyaporphine 2 (AK-2-202) was necessary for efficient receptor binding and antagonism.
Collapse
Affiliation(s)
- Angela F Ku
- Department of Pharmacological and Pharmaceutical Sciences , University of Houston , Science and Research Building 2 , Houston , Texas 77204 , USA .
| | - Gregory D Cuny
- Department of Pharmacological and Pharmaceutical Sciences , University of Houston , Science and Research Building 2 , Houston , Texas 77204 , USA .
| |
Collapse
|
7
|
Kallepu S, Kavitha M, Yeeravalli R, Manupati K, Jadav SS, Das A, Mainkar PS, Chandrasekhar S. Total Synthesis of Desmethyl Jahanyne and Its Lipo-Tetrapeptide Conjugates Derived from Parent Skeleton as BCL-2-Mediated Apoptosis-Inducing Agents. ACS OMEGA 2018; 3:63-75. [PMID: 30023766 PMCID: PMC6045489 DOI: 10.1021/acsomega.7b01634] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/25/2017] [Accepted: 12/21/2017] [Indexed: 05/25/2023]
Abstract
The total synthesis of highly potent and scarcely available marine natural product (-)-jahanyne was attempted resulting in a solution-phase synthesis of pruned versions with comparable activity. A simple and facile synthetic route was employed for the preparation of pruned congeners and would be scalable. The lipophilic tail of the natural product was synthesized from R-(+)-citronellol, utilizing easily available chemicals. All the synthesized compounds were screened for apoptotic activity against a panel of cell lines. These compounds depicted marked binding to B cell lymphoma 2 till 50 °C in cellular thermal shift analysis.
Collapse
Affiliation(s)
- Shivakrishna Kallepu
- Natural
Products Chemistry Division, Centre for Chemical Biology,
and Medicinal Chemistry
& Biotechnology, CSIR-Indian Institute
of Chemical Technology (CSIR-IICT), Hyderabad 500007, India
| | - Minnapuram Kavitha
- Natural
Products Chemistry Division, Centre for Chemical Biology,
and Medicinal Chemistry
& Biotechnology, CSIR-Indian Institute
of Chemical Technology (CSIR-IICT), Hyderabad 500007, India
- Academy
of Scientific and Innovative Research (AcSIR), New Delhi 110020, India
| | - Ragini Yeeravalli
- Natural
Products Chemistry Division, Centre for Chemical Biology,
and Medicinal Chemistry
& Biotechnology, CSIR-Indian Institute
of Chemical Technology (CSIR-IICT), Hyderabad 500007, India
- Academy
of Scientific and Innovative Research (AcSIR), New Delhi 110020, India
| | - Kanakaraju Manupati
- Natural
Products Chemistry Division, Centre for Chemical Biology,
and Medicinal Chemistry
& Biotechnology, CSIR-Indian Institute
of Chemical Technology (CSIR-IICT), Hyderabad 500007, India
- Academy
of Scientific and Innovative Research (AcSIR), New Delhi 110020, India
| | - Surender Singh Jadav
- Natural
Products Chemistry Division, Centre for Chemical Biology,
and Medicinal Chemistry
& Biotechnology, CSIR-Indian Institute
of Chemical Technology (CSIR-IICT), Hyderabad 500007, India
| | - Amitava Das
- Natural
Products Chemistry Division, Centre for Chemical Biology,
and Medicinal Chemistry
& Biotechnology, CSIR-Indian Institute
of Chemical Technology (CSIR-IICT), Hyderabad 500007, India
- Academy
of Scientific and Innovative Research (AcSIR), New Delhi 110020, India
| | - Prathama S. Mainkar
- Natural
Products Chemistry Division, Centre for Chemical Biology,
and Medicinal Chemistry
& Biotechnology, CSIR-Indian Institute
of Chemical Technology (CSIR-IICT), Hyderabad 500007, India
- Academy
of Scientific and Innovative Research (AcSIR), New Delhi 110020, India
| | - Srivari Chandrasekhar
- Natural
Products Chemistry Division, Centre for Chemical Biology,
and Medicinal Chemistry
& Biotechnology, CSIR-Indian Institute
of Chemical Technology (CSIR-IICT), Hyderabad 500007, India
- Academy
of Scientific and Innovative Research (AcSIR), New Delhi 110020, India
| |
Collapse
|
8
|
Michel MC, Charlton SJ. Biased Agonism in Drug Discovery-Is It Too Soon to Choose a Path? Mol Pharmacol 2018; 93:259-265. [PMID: 29326242 DOI: 10.1124/mol.117.110890] [Citation(s) in RCA: 63] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2017] [Accepted: 01/01/2018] [Indexed: 12/13/2022] Open
Abstract
A single receptor can activate multiple signaling pathways that have distinct or even opposite effects on cell function. Biased agonists stabilize receptor conformations preferentially stimulating one of these pathways, and therefore allow a more targeted modulation of cell function and treatment of disease. Dedicated development of biased agonists has led to promising drug candidates in clinical development, such as the G protein-biased µ opioid receptor agonist oliceridine. However, leveraging the theoretical potential of biased agonism for drug discovery faces several challenges. Some of these challenges are technical, such as techniques for quantitative analysis of bias and development of suitable screening assays; others are more fundamental, such as the need to robustly identify in a very early phase which cell type harbors the cellular target of the drug candidate, which signaling pathway leads to the desired therapeutic effect, and how these pathways may be modulated in the disease to be treated. We conclude that biased agonism has potential mainly in the treatment of conditions with a well-understood pathophysiology; in contrast, it may increase effort and commercial risk under circumstances where the pathophysiology has been less well defined, as is the case with many highly innovative treatments.
Collapse
Affiliation(s)
- Martin C Michel
- Department of Pharmacology, Johannes Gutenberg University, Mainz, Germany (M.C.M.); Department of Life Sciences, University of Nottingham, Nottingham, United Kingdom (S.J.C.); and Excellerate Biosciences Ltd., MediCity, Nottingham, United Kingdom (S.J.C.)
| | - Steven J Charlton
- Department of Pharmacology, Johannes Gutenberg University, Mainz, Germany (M.C.M.); Department of Life Sciences, University of Nottingham, Nottingham, United Kingdom (S.J.C.); and Excellerate Biosciences Ltd., MediCity, Nottingham, United Kingdom (S.J.C.)
| |
Collapse
|
9
|
Harper BH, Wang L, Zhu C, Kar NF, Li B, Moyes CR, Goble SD, Costa M, Dingley K, Di Salvo J, Ha SN, Hurley A, Li X, Miller RR, Nagabukuro H, Salituro GM, Smith S, Struthers M, Hale JJ, Edmondson SD, Berger R. Investigation of piperazine benzamides as human β 3 adrenergic receptor agonists for the treatment of overactive bladder. Bioorg Med Chem Lett 2017; 27:1094-1098. [PMID: 28089699 DOI: 10.1016/j.bmcl.2016.12.033] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2016] [Revised: 12/07/2016] [Accepted: 12/09/2016] [Indexed: 01/15/2023]
Abstract
The synthesis of a novel class of piperazine benzamide (reverse amides) targeting the human β3-adrenergic receptor for the treatment of overactive bladder (OAB) is described. The SAR studies directed towards maintaining well established β3 potency and selectivities while improving the overall pharmacokinetic profile in the reverse amide class will be evaluated. The results and consequences associated with functional activity at the norepinephrine transporter (NET) will also be discussed.
Collapse
Affiliation(s)
- Bart H Harper
- Merck & Co., Inc., 126 E. Lincoln Ave., Rahway, NJ 07065, United States.
| | - Liping Wang
- Merck & Co., Inc., 126 E. Lincoln Ave., Rahway, NJ 07065, United States
| | - Cheng Zhu
- Merck & Co., Inc., 126 E. Lincoln Ave., Rahway, NJ 07065, United States
| | - Nam F Kar
- Merck & Co., Inc., 126 E. Lincoln Ave., Rahway, NJ 07065, United States
| | - Bing Li
- Merck & Co., Inc., 126 E. Lincoln Ave., Rahway, NJ 07065, United States
| | | | - Stephen D Goble
- Merck & Co., Inc., 126 E. Lincoln Ave., Rahway, NJ 07065, United States
| | - Melissa Costa
- Merck & Co., Inc., 126 E. Lincoln Ave., Rahway, NJ 07065, United States
| | - Karen Dingley
- Merck & Co., Inc., 126 E. Lincoln Ave., Rahway, NJ 07065, United States
| | - Jerry Di Salvo
- Merck & Co., Inc., 126 E. Lincoln Ave., Rahway, NJ 07065, United States
| | - Sookhee N Ha
- Merck & Co., Inc., 126 E. Lincoln Ave., Rahway, NJ 07065, United States
| | - Amanda Hurley
- Merck & Co., Inc., 126 E. Lincoln Ave., Rahway, NJ 07065, United States
| | - Xiaofang Li
- Merck & Co., Inc., 126 E. Lincoln Ave., Rahway, NJ 07065, United States
| | - Randy R Miller
- Merck & Co., Inc., 126 E. Lincoln Ave., Rahway, NJ 07065, United States
| | | | - Gino M Salituro
- Merck & Co., Inc., 126 E. Lincoln Ave., Rahway, NJ 07065, United States
| | - Sean Smith
- Merck & Co., Inc., 126 E. Lincoln Ave., Rahway, NJ 07065, United States
| | - Mary Struthers
- Merck & Co., Inc., 126 E. Lincoln Ave., Rahway, NJ 07065, United States
| | - Jeffrey J Hale
- Merck & Co., Inc., 126 E. Lincoln Ave., Rahway, NJ 07065, United States
| | - Scott D Edmondson
- Merck & Co., Inc., 126 E. Lincoln Ave., Rahway, NJ 07065, United States
| | - Richard Berger
- Merck & Co., Inc., 126 E. Lincoln Ave., Rahway, NJ 07065, United States
| |
Collapse
|
10
|
Di Salvo J, Nagabukuro H, Wickham LA, Abbadie C, DeMartino JA, Fitzmaurice A, Gichuru L, Kulick A, Donnelly MJ, Jochnowitz N, Hurley AL, Pereira A, Sanfiz A, Veronin G, Villa K, Woods J, Zamlynny B, Zycband E, Salituro G, Frenkl T, Weber AE, Edmondson SD, Struthers M. Pharmacological Characterization of a Novel Beta 3 Adrenergic Agonist, Vibegron: Evaluation of Antimuscarinic Receptor Selectivity for Combination Therapy for Overactive Bladder. J Pharmacol Exp Ther 2016; 360:346-355. [DOI: 10.1124/jpet.116.237313] [Citation(s) in RCA: 40] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2016] [Accepted: 12/05/2016] [Indexed: 12/17/2022] Open
|
11
|
Edmondson SD, Zhu C, Kar NF, Di Salvo J, Nagabukuro H, Sacre-Salem B, Dingley K, Berger R, Goble SD, Morriello G, Harper B, Moyes CR, Shen DM, Wang L, Ball R, Fitzmaurice A, Frenkl T, Gichuru LN, Ha S, Hurley AL, Jochnowitz N, Levorse D, Mistry S, Miller RR, Ormes J, Salituro GM, Sanfiz A, Stevenson AS, Villa K, Zamlynny B, Green S, Struthers M, Weber AE. Discovery of Vibegron: A Potent and Selective β3 Adrenergic Receptor Agonist for the Treatment of Overactive Bladder. J Med Chem 2016; 59:609-23. [DOI: 10.1021/acs.jmedchem.5b01372] [Citation(s) in RCA: 63] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Scott D. Edmondson
- Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States
| | - Cheng Zhu
- Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States
| | - Nam Fung Kar
- Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States
| | - Jerry Di Salvo
- Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States
| | - Hiroshi Nagabukuro
- Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States
| | - Beatrice Sacre-Salem
- Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States
| | - Karen Dingley
- Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States
| | - Richard Berger
- Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States
| | - Stephen D. Goble
- Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States
| | - Gregori Morriello
- Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States
| | - Bart Harper
- Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States
| | - Christopher R. Moyes
- Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States
| | - Dong-Ming Shen
- Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States
| | - Liping Wang
- Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States
| | - Richard Ball
- Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States
| | - Aileen Fitzmaurice
- Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States
| | - Tara Frenkl
- Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States
| | - Loise N. Gichuru
- Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States
| | - Sookhee Ha
- Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States
| | - Amanda L. Hurley
- Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States
| | - Nina Jochnowitz
- Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States
| | - Dorothy Levorse
- Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States
| | - Shruty Mistry
- Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States
| | - Randy R. Miller
- Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States
| | - James Ormes
- Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States
| | - Gino M. Salituro
- Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States
| | - Anthony Sanfiz
- Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States
| | - Andra S. Stevenson
- Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States
| | - Katherine Villa
- Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States
| | - Beata Zamlynny
- Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States
| | - Stuart Green
- Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States
| | - Mary Struthers
- Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States
| | - Ann E. Weber
- Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States
| |
Collapse
|
12
|
Discovery of benzamides as potent human β3 adrenergic receptor agonists. Bioorg Med Chem Lett 2015; 26:55-9. [PMID: 26590100 DOI: 10.1016/j.bmcl.2015.11.030] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2015] [Revised: 11/06/2015] [Accepted: 11/09/2015] [Indexed: 11/21/2022]
Abstract
The paper will describe the synthesis and SAR studies that led to the discovery of benzamide (reverse amide) as potent and selective human β3-adrenergic receptor agonist. Based on conformationally restricted pyrrolidine scaffold we discovered earlier, pyrrolidine benzoic acid intermediate 22 was synthesized. From library synthesis and further optimization efforts, several structurally diverse reverse amides such as 24c and 24i were found to have excellent human β3-adrenergic potency and good selectivity over the β1 and β2 receptors. In addition to human β1, β2, β3 and hERG data, PK of selected compounds will be described.
Collapse
|
13
|
Andersson KE. Drug therapy of overactive bladder--what is coming next? Korean J Urol 2015; 56:673-9. [PMID: 26495067 PMCID: PMC4610893 DOI: 10.4111/kju.2015.56.10.673] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2015] [Accepted: 09/03/2015] [Indexed: 01/25/2023] Open
Abstract
After the approval and introduction of mirabegron, tadalafil, and botulinum toxin A for treatment of lower urinary tract symptoms/overactive bladder, focus of interest has been on their place in therapy versus the previous gold standard, antimuscarinics. However, since these agents also have limitations there has been increasing interest in what is coming next - what is in the pipeline? Despite progress in our knowledge of different factors involved in both peripheral and central modulation of lower urinary tract dysfunction, there are few innovations in the pipe-line. Most developments concern modifications of existing principles (antimuscarinics, β3-receptor agonists, botulinum toxin A). However, there are several new and old targets/drugs of potential interest for further development, such as the purinergic and cannabinoid systems and the different members of the transient receptor potential channel family. However, even if there seems to be good rationale for further development of these principles, further exploration of their involvement in lower urinary tract function/dysfunction is necessary.
Collapse
Affiliation(s)
- Karl-Erik Andersson
- Institute for Regenerative Medicine, Wake Forest University School of Medicine, Winston Salem, NC, USA. ; Aarhus Institute for Advanced Sciences, Aarhus University, Aarhus, Denmark
| |
Collapse
|
14
|
Wada Y, Shirahashi H, Iwanami T, Ogawa M, Nakano S, Morimoto A, Kasahara KI, Tanaka E, Takada Y, Ohashi S, Mori M, Shuto S. Discovery of Novel Indazole Derivatives as Highly Potent and Selective Human β3-Adrenergic Receptor Agonists with the Possibility of Having No Cardiovascular Side Effects. J Med Chem 2015; 58:6048-57. [PMID: 26125514 DOI: 10.1021/acs.jmedchem.5b00638] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Abstract
Novel indazole derivatives were prepared and evaluated for their biological activity and cardiovascular safety profile as human β3-adrenergic receptor (AR) agonists. Although the initial hit compound 5 exhibited significant β3-AR agonistic activity (EC50 = 21 nM), it also exhibited agonistic activity at the α1A-AR (EC50 = 219 nM, selectivity: α1A/β3 = 10-fold). The major metabolite of 5, which was an oxidative product at the indazole 3-methyl moiety, gave a clue to a strategy for improvement of the selectivity for β3-AR agonistic activity versus α1A-AR agonistic activity. Thus, modification of the 3-substituent of the indazole moiety effectively improved the selectivity to develop compound 11 with potent β3-AR agonistic activity (EC50 = 13 nM) and high selectivity (α1A/β3 = >769-fold). Compound 11 was also inactive toward β1 and β2-ARs and showed dose dependent β3-AR mediated relaxation of marmoset urinary bladder smooth muscle, while it did not obviously affect heart rate or blood pressure (iv, 3 mg/kg) in anesthetized rats.
Collapse
Affiliation(s)
- Yasuhiro Wada
- †Pharmaceutical Research Center, Asahi Kasei Pharma Corporation, 632-1, Mifuku, Izunokuni-shi, Shizuoka 410-2321, Japan
| | - Hiromitsu Shirahashi
- †Pharmaceutical Research Center, Asahi Kasei Pharma Corporation, 632-1, Mifuku, Izunokuni-shi, Shizuoka 410-2321, Japan
| | - Taisuke Iwanami
- †Pharmaceutical Research Center, Asahi Kasei Pharma Corporation, 632-1, Mifuku, Izunokuni-shi, Shizuoka 410-2321, Japan
| | - Masami Ogawa
- †Pharmaceutical Research Center, Asahi Kasei Pharma Corporation, 632-1, Mifuku, Izunokuni-shi, Shizuoka 410-2321, Japan
| | - Seiji Nakano
- †Pharmaceutical Research Center, Asahi Kasei Pharma Corporation, 632-1, Mifuku, Izunokuni-shi, Shizuoka 410-2321, Japan
| | - Akifumi Morimoto
- †Pharmaceutical Research Center, Asahi Kasei Pharma Corporation, 632-1, Mifuku, Izunokuni-shi, Shizuoka 410-2321, Japan
| | - Ken-ichi Kasahara
- †Pharmaceutical Research Center, Asahi Kasei Pharma Corporation, 632-1, Mifuku, Izunokuni-shi, Shizuoka 410-2321, Japan
| | - Eiichi Tanaka
- †Pharmaceutical Research Center, Asahi Kasei Pharma Corporation, 632-1, Mifuku, Izunokuni-shi, Shizuoka 410-2321, Japan
| | - Yoshio Takada
- †Pharmaceutical Research Center, Asahi Kasei Pharma Corporation, 632-1, Mifuku, Izunokuni-shi, Shizuoka 410-2321, Japan
| | - Shigeki Ohashi
- †Pharmaceutical Research Center, Asahi Kasei Pharma Corporation, 632-1, Mifuku, Izunokuni-shi, Shizuoka 410-2321, Japan
| | - Mutsuhiro Mori
- †Pharmaceutical Research Center, Asahi Kasei Pharma Corporation, 632-1, Mifuku, Izunokuni-shi, Shizuoka 410-2321, Japan
| | | |
Collapse
|
15
|
Soriano-Ursúa MA, Trujillo-Ferrara JG, Arias-Montaño JA, Villalobos-Molina R. Insights into a defined secondary binding region on β-adrenoceptors and putative roles in ligand binding and drug design. MEDCHEMCOMM 2015. [DOI: 10.1039/c5md00011d] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Putative roles of a secondary binding region shared among beta-adrenoceptors.
Collapse
Affiliation(s)
- M. A. Soriano-Ursúa
- Posgraduate and Research Section
- Escuela Superior de Medicina
- Instituto Politécnico Nacional
- Mexico City
- Mexico
| | - J. G. Trujillo-Ferrara
- Posgraduate and Research Section
- Escuela Superior de Medicina
- Instituto Politécnico Nacional
- Mexico City
- Mexico
| | - J. A. Arias-Montaño
- Departamento de Fisiología
- Biofísica y Neurociencias. Centro de Investigación y de Estudios Avanzados del IPN
- Mexico City
- Mexico
| | - R. Villalobos-Molina
- Unidad de Investigación en Biomedicina
- Facultad de Estudios Superiores Iztacala
- Universidad Nacional Autónoma de México
- Tlalnepantla
- Mexico
| |
Collapse
|